The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis
- 31 October 2001
- journal article
- clinical trial
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 108 (4) , 530-536
- https://doi.org/10.1067/mai.2001.118596
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Phosphodiesterase 4 Inhibitors and the Treatment of AsthmaDrugs, 2000
- Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitorsBiochemical Pharmacology, 1999
- Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytesEuropean Journal of Pharmacology, 1999
- Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trialsBMJ, 1998
- Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamolBritish Journal of Pharmacology, 1998
- Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthmaCanadian Journal of Physiology and Pharmacology, 1998
- Allergic rhinitis and asthma: How important is the link?☆☆☆★Journal of Allergy and Clinical Immunology, 1997
- Economic Outcomes for the Treatment of Allergic RhinitisPharmacoEconomics, 1996
- Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history.Thorax, 1991
- The cellular response of the human allergic mucosa to natural allergen exposureJournal of Allergy and Clinical Immunology, 1988